AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter

ALACHUA, FL --(Marketwired - May 05, 2015) - AxoGen, Inc. ( NASDAQ : AXGN ), a leading medical technology company focused on the $1.6 billion peripheral nerve repair market, reported record revenue of $4.95 million for the first quarter ended March 31, 2015 compared to $3.14 million in the year-ago first quarter.

"The market's continued adoption of our proprietary portfolio of nerve repair products -- Avance ® Nerve Graft, AxoGuard ® Nerve Connector and AxoGuard ® Nerve Protector -- and our solid sales execution delivered another record quarter with revenue increasing 58% year-over-year," commented Karen Zaderej, Chief Executive Officer. "Despite some negative effects of severe weather in January and February, this quarter continues our strong growth momentum of the last 2 years and is directly related to our focus on executing our sales and marketing strategy." 

2015 First Quarter Financial Results

For the first quarter ended March 31, 2015, revenue totaled $4.95 million, a 58% increase compared to $3.14 million in the prior year first quarter. The Company reported gross margin expanded to 80.1% compared to 77.7% in the first quarter ended March 31, 2014. Net loss was $3.6 million, or $0.16 per share compared to a net loss of $4.2 million, or $0.24 per share in the year-ago first quarter. The weighted average common shares outstanding for the 2015 first quarter were approximately 22.5 million shares compared to 17.4 million shares in the 2014 first quarter. 

As of March 31, 2015, cash and cash equivalents totaled $19.3 million which includes $13.6 million of net proceeds related to the public common stock offering in February.

2015 Guidance

Given the market's increasing awareness of AxoGen's product portfolio and the Company's plans to expand its sales footprint and sales pipeline, AxoGen is reaffirming its 2015 full year revenue outlook of at least $24 million with annual gross margin in the mid to high 70% range.

Conference Call The Company will host a conference call and webcast for the investment community following the release at 4:30 PM ET. Investors interested in participating by phone are invited to call toll free at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. Those interested in joining via the webcast, should visit http://axogeninc.equisolvewebcast.com/q1-2015 .

Following the conference call, a replay will be available on the Company's website at www.AxoGenInc.com , under 'Investors.'

About AxoGen, Inc. AxoGen ( NASDAQ : AXGN ) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance ®  Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard ®  Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard ®  Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance ®  Nerve Graft is processed in the United States by AxoGen. AxoGuard ®  Nerve Connector and AxoGuard ®  Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Cautionary Statement Concerning Forward-Looking Statements This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the closing of the over-allotment option and the AxoGen's proposed use of proceeds. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development, product potential, or the intended use of proceeds from the offering. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

               
AXOGEN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
 
               
    March 31,        
2015   December 31,
(unaudited)   2014
Assets              
Current assets:              
  Cash and cash equivalents $ 19,255,725     $ 8,215,791  
  Accounts receivable   3,161,588       2,872,308  
  Inventory   3,337,898       3,213,620  
  Prepaid expenses and other   259,948       109,369  
    Total current assets   26,015,159       14,411,088  
Property and equipment, net   583,420       619,028  
Intangible assets   597,453       577,174  
Deferred financing costs   939,894       793,499  
  $ 28,135,926     $ 16,400,789  
Liabilities and Shareholders' Equity (Deficit)              
Current liabilities:              
  Accounts payable and accrued expenses $ 3,423,272     $ 2,431,194  
  Current Deferred Revenue   14,118       14,118  
    Total current liabilities   3,437,390       2,445,312  
Note Payable - Revenue Interest Purchase Agreement   25,269,050       25,085,777  
Long Term Deferred Revenue   109,984       115,380  
    Total liabilities   28,816,424       27,646,469  
Shareholders' equity (deficit):              
  Common stock, $.01 par value; 50,000,000 shares authorized; 24,926,014 and 19,488,814 shares issued and outstanding   249,260       194,888  
               
  Additional paid-in capital   92,761,697       78,675,686  
  Accumulated deficit   (93,691,455 )     (90,116,254 )
    Total shareholders' equity (deficit)   (680,498 )     (11,245,680 )
  $ 28,135,926     $ 16,400,789  
               
               
AXOGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months ended March 31, 2015 and 2014
(unaudited)
               
  2015   2014
Revenues $ 4,951,316     $ 3,138,256  
Cost of goods sold   982,881       701,300  
    Gross profit   3,968,435       2,436,956  
Costs and expenses:              
  Sales and marketing   3,932,522       2,720,707  
  Research and development   671,036       812,615  
  General and administrative   1,908,581       1,894,776  
    Total costs and expenses   6,512,139       5,428,098  
    Loss from operations   (2,543,704 )     (2,991,142 )
Other expense:              
  Interest expense   (994,748 )     (1,191,317 )
  Interest expense - deferred financing costs   (33,746 )     (51,216 )
  Other expense   (3,003 )     (5,889 )
    Total other expense   (1,031,497 )     (1,248,422 )
Net loss $ (3,575,201 )   $ (4,239,564 )
Weighted Average Common Shares outstanding - basic and diluted   22,517,361       17,383,786  
Loss Per Common share - basic and diluted $ (0.16 )   $ (0.24 )
               
               
AXOGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months ended March 31, 2015 and 2014
(unaudited)
               
  2015   2014
Cash flows from operating activities:              
  Net loss $ (3,575,201 )   $ (4,239,564 )
  Adjustments to reconcile net loss to net cash used for operating activities:              
    Depreciation   41,898       33,944  
    Amortization of intangible assets   11,772       10,955  
    Amortization of deferred financing costs   33,746       51,216  
    Share-based compensation   368,249       257,542  
    Stock grants   --       60,125  
    Interest added to note payable   183,273       891,845  
    Change in assets and liabilities:              
      Accounts receivable   (289,280 )     (71,458 )
      Inventory   (124,278 )     (67,661 )
      Prepaid expenses and other   (150,579 )     101,230  
      Accounts payable and accrued expenses   992,078       (175,196 )
      Deferred revenue   (5,396 )     (3,571 )
Net cash used for operating activities   (2,513,718 )     (3,150,593 )
               
Cash flows from investing activities:              
  Purchase of property and equipment   (6,288 )     (195,482 )
  Acquisition of intangible assets   (32,051 )     (8,346 )
Net cash used for investing activities   (38,339 )     (203,828 )
               
Cash flows from financing activities:              
  Proceeds from exercise of stock options   --       92,424  
  Proceeds from issuance of common stock   13,772,133       --  
  Debt issuance costs   (180,142 )     --  
Net cash provided by financing activities   13,591,991       92,424  
               
Net increase/(decrease) in cash and cash equivalents   11,039,934       (3,261,997 )
Cash and cash equivalents, beginning of year   8,215,791       20,069,750  
Cash and cash equivalents, end of period $ 19,255,725     $ 16,807,753  
               
Supplemental disclosures of cash flow activity:              
  Cash paid for interest $ 803,607     $ 303,919  
                 

Contact: AxoGen, Inc. Lee Robert "Bob" Johnston Chief Financial Officer 386.462.6856 InvestorRelations@AxoGenInc.com EVC Group Michael Polyviou  212.850.6020 mpolyviou@evcgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 60

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 54

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 167

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 101

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 59

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
Everyday Dose Tests Coffee in a New Pocket Format Today

Updated Category News Views 66

Coffee has finally wandered into the candy aisle, and I cannot decide whether that is clever or mildly exhausting. Everyday Dose and Austin-based Le Lick have launched Le Latte, a limited-batch coffee-flavored electrolyte lollipop aimed at adults who want caffeine without hauling around a cup. It is an odd little product, sure, but odd is often where consumer brands find...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 76

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading

Top 5 Most Recently Viewed Articles

Exyte's New Leadership: Katrien Verlinden Takes Charge

Updated Category News Views 262

Exyte Appoints Katrien Verlinden as President of ATF Exyte is excited to announce the appointment of Katrien Verlinden as the new President of its Global Business Unit (GBU) Advanced Technology Facilities (ATF). This significant change is set to take effect soon, marking a pivotal moment for the company. Leadership Experience and Vision Katrien Verlinden brings over 25...

Continue Reading
Webull's Exciting New Deposit Bonus Sparks Retail Trading Surge

Updated Category News Views 241

Webull Set to Captivate Retail Investors with Innovative Offers Retail investors have been making a notable comeback in U.S. markets, engaging at levels almost unmatched since the meme-stock frenzy of 2021. This renewed enthusiasm has sparked a competitive race among trading platforms eager to seize this opportunity. Webull stands out with its timely initiative,...

Continue Reading
SMCP Reports Strong Q1 2025 Performance with Organic Growth

Updated Category News Views 245

SMCP Reports Solid Growth in Q1 2025 SMCP has announced a remarkable increase in its sales for the first quarter of 2025, demonstrating robust growth across numerous key markets. With total sales reaching €297 million, this marks a 2.6% hike on an organic basis compared to the previous year's performance, where sales were at €287 million. This growth can be attributed...

Continue Reading
Ambow Education Reports Strong Financial Results for 2025

Updated Category News Views 157

Ambow Education Delivers Impressive Results for 2025 Ambow Education Holding Ltd. (AMBO), a leader in AI-driven hybrid education solutions, has made headlines with a recent release that highlights its robust financial performance in 2025. The company reported significant growth and achievements that mark a transformative period for its operations. Unveiling Financial...

Continue Reading
Fundy Designer Expands Design Library for Photographers

Updated Category News Views 177

Fundy Designer Unveils New Templates for Photographers As the busy fall sales season approaches, Fundy Designer has upgraded its Design Library, now boasting over $10,000 in templates for its subscribers. This update brings a fresh assortment of holiday cards and senior graduation album templates, designed to meet the varied needs of professional photographers. A Diverse...

Continue Reading